Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Michael S. Jacobs, RPh
MSA & Associates
Sandy Springs, GA
Authored Items
Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis
Kavita Nair, PhD
,
Michael S. Jacobs, RPh
,
Vahram Ghushchyan, PhD
,
Ahmad Naim, MD
March/April 2013 Vol 6, No 2
in
Original Research
Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit
Michael S. Jacobs, RPh
,
James T. Kenney, RPh, MBA
,
Kjel A. Johnson, PharmD, BcPS, FccP, FAMcP
July/August 2012, Vol 5, No 5
in
Practice Management
Healthcare Costs Associated with Switching from Brand to Generic Levothyroxine
Michael Katz, PharmD
,
Michael S. Jacobs, RPh
,
Joseph Scherger, MD, MPH
,
Scott Conard, MD
,
Leslie Montejano, CCRP
,
Stella Chang, MPH
March/April 2010, Vol 3, No 2
in
Original Research
Last modified: December 5, 2017